ALK-targeted therapy for lung cancer: ready for prime time.

Hatim Husain, Charles M. Rudin

Research output: Contribution to journalArticle

Abstract

Lung cancer remains the leading cause of cancer-related death in the United States. Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation. One of the most recent examples of this has been definition of translocations and functional dysregulation of the anaplastic lymphoma kinase (ALK) gene in a subset of patients with non-small-cell lung cancer. The pace of research progress in this area has been remarkable: chromosomal rearrangements involving this gene in lung cancer were first reported in 2007 by a team of investigators in Japan. Less than 3 years later, an early-phase clinical trial of a targeted ALK inhibitor has yielded impressive responses in patients with advanced lung cancer containing ALK rearrangements, and mechanisms of acquired resistance to ALK-targeted therapy are being reported. A definitive study randomizing patients with ALK-mutant lung cancer to crizotinib (also known as PF-02341066 or 1066) versus standard therapy has recently completed enrollment.Taken together, these data describe a trajectory of research progress from basic discovery science to real-world implementation that should serve as a model for future integration of preclinical and clinical therapeutic research.

Original languageEnglish (US)
Pages (from-to)597-601
Number of pages5
JournalOncology
Volume25
Issue number7
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Lung Neoplasms
Research
Therapeutic Human Experimentation
Therapeutics
Critical Pathways
Gene Rearrangement
Non-Small Cell Lung Carcinoma
Neoplasms
Cell Survival
Japan
Carcinogenesis
Research Personnel
Cell Proliferation
anaplastic lymphoma kinase
Clinical Trials
Lung
Mutation
Genes
crizotinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Husain, H., & Rudin, C. M. (2011). ALK-targeted therapy for lung cancer: ready for prime time. Oncology, 25(7), 597-601.

ALK-targeted therapy for lung cancer : ready for prime time. / Husain, Hatim; Rudin, Charles M.

In: Oncology, Vol. 25, No. 7, 06.2011, p. 597-601.

Research output: Contribution to journalArticle

Husain, H & Rudin, CM 2011, 'ALK-targeted therapy for lung cancer: ready for prime time.', Oncology, vol. 25, no. 7, pp. 597-601.
Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for prime time. Oncology. 2011 Jun;25(7):597-601.
Husain, Hatim ; Rudin, Charles M. / ALK-targeted therapy for lung cancer : ready for prime time. In: Oncology. 2011 ; Vol. 25, No. 7. pp. 597-601.
@article{ae5743134d304b419be860b209a75b58,
title = "ALK-targeted therapy for lung cancer: ready for prime time.",
abstract = "Lung cancer remains the leading cause of cancer-related death in the United States. Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation. One of the most recent examples of this has been definition of translocations and functional dysregulation of the anaplastic lymphoma kinase (ALK) gene in a subset of patients with non-small-cell lung cancer. The pace of research progress in this area has been remarkable: chromosomal rearrangements involving this gene in lung cancer were first reported in 2007 by a team of investigators in Japan. Less than 3 years later, an early-phase clinical trial of a targeted ALK inhibitor has yielded impressive responses in patients with advanced lung cancer containing ALK rearrangements, and mechanisms of acquired resistance to ALK-targeted therapy are being reported. A definitive study randomizing patients with ALK-mutant lung cancer to crizotinib (also known as PF-02341066 or 1066) versus standard therapy has recently completed enrollment.Taken together, these data describe a trajectory of research progress from basic discovery science to real-world implementation that should serve as a model for future integration of preclinical and clinical therapeutic research.",
author = "Hatim Husain and Rudin, {Charles M.}",
year = "2011",
month = "6",
language = "English (US)",
volume = "25",
pages = "597--601",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "7",

}

TY - JOUR

T1 - ALK-targeted therapy for lung cancer

T2 - ready for prime time.

AU - Husain, Hatim

AU - Rudin, Charles M.

PY - 2011/6

Y1 - 2011/6

N2 - Lung cancer remains the leading cause of cancer-related death in the United States. Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation. One of the most recent examples of this has been definition of translocations and functional dysregulation of the anaplastic lymphoma kinase (ALK) gene in a subset of patients with non-small-cell lung cancer. The pace of research progress in this area has been remarkable: chromosomal rearrangements involving this gene in lung cancer were first reported in 2007 by a team of investigators in Japan. Less than 3 years later, an early-phase clinical trial of a targeted ALK inhibitor has yielded impressive responses in patients with advanced lung cancer containing ALK rearrangements, and mechanisms of acquired resistance to ALK-targeted therapy are being reported. A definitive study randomizing patients with ALK-mutant lung cancer to crizotinib (also known as PF-02341066 or 1066) versus standard therapy has recently completed enrollment.Taken together, these data describe a trajectory of research progress from basic discovery science to real-world implementation that should serve as a model for future integration of preclinical and clinical therapeutic research.

AB - Lung cancer remains the leading cause of cancer-related death in the United States. Ongoing research into the molecular basis of lung cancer has yielded insight into various critical pathways that are deregulated in lung tumorigenesis, and in particular key driver mutations integral to cancer cell survival and proliferation. One of the most recent examples of this has been definition of translocations and functional dysregulation of the anaplastic lymphoma kinase (ALK) gene in a subset of patients with non-small-cell lung cancer. The pace of research progress in this area has been remarkable: chromosomal rearrangements involving this gene in lung cancer were first reported in 2007 by a team of investigators in Japan. Less than 3 years later, an early-phase clinical trial of a targeted ALK inhibitor has yielded impressive responses in patients with advanced lung cancer containing ALK rearrangements, and mechanisms of acquired resistance to ALK-targeted therapy are being reported. A definitive study randomizing patients with ALK-mutant lung cancer to crizotinib (also known as PF-02341066 or 1066) versus standard therapy has recently completed enrollment.Taken together, these data describe a trajectory of research progress from basic discovery science to real-world implementation that should serve as a model for future integration of preclinical and clinical therapeutic research.

UR - http://www.scopus.com/inward/record.url?scp=80052910424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052910424&partnerID=8YFLogxK

M3 - Article

C2 - 21888258

VL - 25

SP - 597

EP - 601

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7

ER -